Merck (MRK) Price Target Lifted at Morgan Stanley as Biopharma Outlook Improves

Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best Blue-Chip Stocks with Growing Dividends. Merck (MRK) Price Target Lifted at Morgan Stanley as Biopharma Outlook Improves Photo by Annie Spratt on Unsplash On December 12, Morgan Stanley lifted its price target on Merck & Co., Inc. (NYSE:MRK) to $102 from $100. The firm kept an Equal Weight rating on the stock. In its 2026 outlook for the biopharma space, the firm said many of the policy concerns that weighed on the sector this year are likely to ...